The State of Melanoma: Emergent Challenges and Opportunities. Read more about The State of Melanoma: Emergent Challenges and Opportunities.
Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy. Read more about Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy.
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Read more about Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Read more about Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Read more about Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Read more about Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. Read more about International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.
Autoantibody Landscape in Patients with Advanced Prostate Cancer. Read more about Autoantibody Landscape in Patients with Advanced Prostate Cancer.
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Read more about Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Read more about Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
